Eisai
Presence
Eisai is one of the...
Eisai is a company listed under the stock ticker 4523 (JP).
Eisai has a direct presence in 11 countries.Eisai has 12 subsidiaries including EA Pharma, Eisai Americas and Eisai Australia.
They are in:
Executives
View the org chart displaying its 102 main executives
Most searched biographies at Eisai
- Haruo Naito, Chief Executive Officer, Representative Executive Off...
- Ryota Miura, Director
- Yumiko Miwa, Director
Create your alert
to follow the executive moves at Eisai.
Pharmaceuticals
Eisai has 1,868 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
- Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Eisai
- EISAI SUPPORTS RELIEF EFFORTS FOR THE EARTHQUAKE OF THE EAST COAST OF TAIWAN | News Release：2024 | Eisai Co., Ltd.
- ANTIEPILEPTIC DRUG FYCOMPA® INJECTION FORMULATION LAUNCHED IN JAPAN | News Release：2024 | Eisai Co., Ltd.
- RESEARCH ON TREATMENTS FOR ALZHEIMER’S DISEASE BASED ON ITS PATHOLOGICAL MECHANISMS RECIEVES AWARD FOR SCIENCE AND TECHNOLOGY (RESEARCH CATEGORY), AS A PART OF FY2024 COMMENDATION FOR SCIENCE AND TECHNOLOGY BY MEXT | News Release：2024 | Eisai Co., Ltd.
- 早期アルツハイマー病治療に対する「レケンビ®」の静注維持投与に関する米国FDAへの生物製剤承認一部変更申請の提出を完了 | ニュースリリース：2024年 | エーザイ株式会社
- DISCOVERY RESEARCH ON DUAL OREXIN RECEPTOR ANTAGONIST LEMBOREXANT HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 2024 | News Release：2024 | Eisai Co., Ltd.
- EISAI’S BRAIN HEALTH SELF-CHECK TOOL “NOUKNOW®” IS CERTIFIED AS “ME-BYO BRAND” BY KANAGAWA PREFECTURE | News Release：2024 | Eisai Co., Ltd.
- Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA | News Release：2024 | Eisai Co., Ltd.
- FRENCH SALES SUBSIDIARY EISAI S.A.S. TO DIVEST RIGHTS FOR LOXAPAC® AND PARKINANE® LP TO CNX THERAPEUTICS | News Release：2024 | Eisai Co., Ltd.
- EISAI TO DIVEST RIGHTS FOR MERISLON® AND MYONAL® IN JAPAN TO KAKEN PHARMACEUTICAL | News Release：2024 | Eisai Co., Ltd.
- Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S. | News Release：2024 | Eisai Co., Ltd.
- View more press releases Close
Social media about Eisai
- Eisai on Wikipedia, Google News & Yahoo Finance
- Eisai on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Toru Moriyama 
